|
About :: Mangement & Advisors
Dave Gonyer, R.Ph., CEO
Dave brings over 20 years in large pharmaceutical and specialty pharmaceutical. Prior to founding Evoke, Dave has held senior management positions both on the commercial and product development sides of the business across many therapeutic areas including CNS, infectious disease, diabetes, gastrointestinal, and allergy. Most recently, Dave had business and product development responsibilities for Medgenex, Inc. a subsidiary Victory Pharma where he initiated two clinical development programs of which both have successfully completed Phase 2 clinical trials. Prior to that he was a founder and Vice President of Commercial Development at Xcel Pharmaceuticals, a specialty pharmaceutical company focused in the CNS arena until its sale to Valeant Pharmaceuticals in 2005 for $280M (USD). While at Xcel, Dave was directly responsible for all aspects of commercial development of their marketed products, including marketing, sales, regulatory, and lifecycle management. During that time he obtained FDA approval of two key inventions for Diastat and Migranal. Dave also held various management positions in both marketing and managed care roles at Dura/Elan Pharmaceuticals. Dave started his pharmaceutical career at Eli Lilly & Company and held numerous commercial roles of increasing responsibility over a decade
Dave is a registered pharmacist and a graduate of the Ferris State University School of Pharmacy.
Matt D'Onofrio, Executive Vice President, Corporate Development
Matt has over 16 years of experience in both large and small pharmaceutical firms. Prior to founding Evoke, Matt was Vice President, Business Development for Victory Pharma, a growing specialty pharma company based in San Diego. Matt led efforts to acquire marketed brands for the growing sales force. Earlier, he was previously Director and Head of West Coast Business Development at Vertex Pharmaceuticals, a biotechnology company, directing partnership efforts associated with the La Jolla research facility as well as other corporate assets. Matt also held various commercial roles of increasing responsibility over a decade at Eli Lilly & Company, including significant experience in worldwide corporate business development. During his licensing career, he has developed and executed license and investment relationships across a wide collection of disease states and technologies with potential value approaching US$1 billion.
Matt earned a B.S. in Chemistry from San Diego State University and a M.B.A. (Finance) from the Marshall School of Business, University of Southern California.
Marilyn R. Carlson, D.M.D., M.D., RAC. - Clinical and Regulatory*
Dr. Marilyn R. Carlson has more than 17 years of industry experience in the development and post-marketing support of drugs, devices, diagnostics and biologics. Her career in the pharmaceutical industry includes Procter & Gamble (OTC healthcare and pharmaceuticals), XOMA (biologics), Advanced Corneal Systems (now ISTA Pharmaceuticals) and Prometheus Laboratories (pharmaceuticals and diagnostics) where she was Chief Medical Officer and Vice President Medical/Regulatory Affairs. In 2004, Marilyn founded entreMeDica, Inc. a San Diego-based consulting company that provides chief medical officer services to the biotechnology and life sciences community. She is also Vice-President of Medical and Regulatory Affairs at Synteract, Inc., a full-service contract research organization.
Marilyn has a BA in anthropology/biology from Hunter College, a D.M.D. from Harvard, completed a dental residency in geriatrics and special patient care at Long Island Jewish-Hillside Medical Center. She also has an M.D. from Case Western Reserve University (Alpha Omega Alpha), completed an internal medicine residency at the Cleveland Clinic Foundation and received Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professionals Society.
Stuart Madden, Ph.D. - Chemistry, Manufacturing & Controls*
Dr. Stuart Madden is Senior Vice President of Strategic Drug Development & Non-Clinical Services for ICON Development Solutions. He is responsible for the management of ICON's Strategic Drug Development, CMC and Preclinical scientific teams. Prior to joining Development Solutions, Dr. Madden was Senior Director of Analytical Sciences for the Elan Corporation, specializing in the development of modified release solid oral dosage forms from conception through NDA submission to commercialization. He has over 20 years in the pharmaceutical industry working on drug development, from proof-of-concept through to commercialization. He has held a number of positions with several international pharmaceutical companies (primarily within research and development), which includes experience in commercial manufacturing, novel degradation chemistry in formulated products. He has contributed to texts on in-vitro/in-vivo correlations, and is a Fellow of the Royal Society of Chemistry.
Dr. Madden earned his BS in Chemistry and his PhD in physical Chemistry from the University of Wales, UK. Dr. Madden then spent 2 years as a Post-doctoral Fellow at San Diego State University, California. His PhD and Post-Doctoral research focused on modeling adsorption mechanisms in high-performance liquid chromatography systems.
*Advisors
|
